U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

The days of cheaper alternatives to popular weight-loss drugs like Wegovy and Zepbound are over for some ... that are not exact copies are still legal. A federal judge March 5 denied a request ...

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are ...

A surge of generics, biosimilars, and innovative therapies is expected in 2025, addressing conditions from cancer to chronic ...

The recent uptick and rise in popularity of GLP-1 drugs for addressing weight loss and obesity has led to an increase in U.S. litigation ...

Supply issues finally started to ease late in 2024, as compounded semaglutide — "copycats" of the patented stuff like Ozempic and Zepbound — began to flood the market when the FDA temporarily ...

Supply issues finally started to ease late in 2024, as compounded semaglutide — "copycats" of the patented stuff like Ozempic and Zepbound — began to flood the market when the FDA temporarily paused ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ ...